Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMG1 | Q96Q15 | 11/20 | 0.78 |
| ▸ | CAMK2D | Q13557 | 5/20 | 0.78 |
| ▸ | CDK1 | P06493 | 5/20 | 0.78 |
| ▸ | CDK2 | P24941 | 5/20 | 0.78 |
| ▸ | MTOR | P42345 | 6/20 | 0.57 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.57 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | BCR | P11274 | 1/20 | 0.56 |
| ▸ | PRKCA | P17252 | 1/20 | 0.56 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.56 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CDK4 | P11802 | 1/20 | 0.55 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.55 |
| ▸ | XBP1 | P17861 | 1/20 | 0.55 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.55 |
| ▸ | CCND1 | P24385 | 1/20 | 0.55 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6947468 | 0.88 | CAMK2D (0.72) | SMG1CAMK2DCDK1CDK2CSNK2A1 | |
| SCHEMBL23374069 | 0.88 | CAMK2D (1.00) | SMG1CAMK2DCDK1CDK2MTOR | |
| SCHEMBL31186805 | 0.88 | CAMK2D (1.00) | SMG1CAMK2DCDK1CDK2MTOR | |
| SCHEMBL6107663 | 0.88 | SMG1 (1.00) | SMG1CAMK2DCDK1CDK2MTOR | |
| SCHEMBL7804203 | 0.83 | SMG1 (0.91) | SMG1CAMK2DCDK1CDK2MTOR | |
| 3-Chloroaniline SCHEMBL8308008 | 0.83 | CAMK2D (0.68) | SMG1CAMK2DCDK1CDK2CSNK2A1 | |
| SCHEMBL6093641 | 0.80 | SMG1 (0.66) | SMG1CAMK2DCDK1CDK2MTOR | |
| SCHEMBL5630858 | 0.79 | SMG1 (0.65) | SMG1CAMK2DCDK1CDK2MTOR | |
| SCHEMBL3513778 | 0.78 | CAMK2D (0.73) | SMG1CAMK2DCDK1CDK2MTOR | |
| SCHEMBL6608384 | 0.78 | SMG1 (0.69) | SMG1CAMK2DCDK1CDK2MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0672041-B1 | PHARMACOLOGICALLY ACTIVE PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 2001-11-14 | — | — | EP | claimed |
| EP-0672041-A1 | PHARMACOLOGICALLY ACTIVE PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1995-09-20 | — | — | EP | claimed |
| WO-1995009853-A1 | PHARMACOLOGICALLY ACTIVE PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | CIBA-GEIGY AG (CH) | 1995-04-13 | — | — | WO | claimed |
| US-7109197-B2 | N-phenyl-4-(4-pyridyl)-2-pyrimidineamine derivatives | SYNGENTA CROP PROTECTION, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1292190-B1 | N-PHENYL-4-(4-PYRIDYL)-2-PYRIMIDINEAMINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2005-08-24 | — | — | EP | disclosed |
| US-20030236256-A1 | N-phenyl-4-(4-pyridyl)-2-pyrimidineamine derivatives | SYNGENTA CROP PROTECTION, INC. | 2003-12-25 | — | — | US | disclosed |
| EP-0672041-B1 | PHARMACOLOGICALLY ACTIVE PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 2001-11-14 | — | — | EP | disclosed |
| EP-0672041-A1 | PHARMACOLOGICALLY ACTIVE PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995009853-A1 | PHARMACOLOGICALLY ACTIVE PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | CIBA-GEIGY AG (CH) | 1995-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236256-A1 | N-phenyl-4-(4-pyridyl)-2-pyrimidineamine derivatives | HRH4, HRH3, HRH2 | SMG1 1422/4885CAMK2D 4728/4885CDK1 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.